Head-to-head · free

Eton Pharmaceuticals, Inc. vs Genmab

ETON vs GMAB — return on capital, cash generation, margins and balance sheet side by side.

ETON

1 / 4

measures where ETON leads

GMAB

3 / 4

measures where GMAB leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureETON · FY2025GMAB
Revenue$80.0M—
Net income(4.6M)—
Revenue growth (yearly, multi-year)38.3%—
Free cash flow$10.2M—
Free cash flow margin12.7%—
Net cash / (debt)——
ROIC—10.1%
Return on equity-18.2%17.5%
Gross margin53.5%93.6%
Operating margin-1.1%33.6%
Net debt / EBITDA1.44x3.13x

Figures are as reported by each company; latest fiscal year shown.

Where Eton Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
$333000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ETON profile →

Where Genmab's cash went

Not reported yet.

Full GMAB profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons